ReviewMarine drugs2013
Marine-derived angiogenesis inhibitors for cancer therapy.
Review in Marine drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 71 citations in OpenAlex.
- Anti-Angiogenic Potential of MarineMolecules (Basel, Switzerland) · 2025Article
- UtilizingArchives of Razi Institute · 2025Review
- In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer.Handbook of experimental pharmacology · 2025Review
- Antiproliferative, Antioxidant, Chemopreventive and Antiangiogenic Potential of Chromatographic Fractions fromInternational journal of molecular sciences · 2023Article
- Inhibiting Angiogenesis by Anti-Cancer Saponins: From Phytochemistry to Cellular Signaling Pathways.Metabolites · 2023Review
- Computational Approaches to Enzyme Inhibition by Marine Natural Products in the Search for New Drugs.Marine drugs · 2023Review
- Substituent-Dependent Divergent Synthesis of 2-(3-Amino-2,4-dicyanophenyl)pyrroles, Pyrrolyldienols and 3-Amino-1-acylethylidene-2-cyanopyrrolizines via Reaction of Acylethynylpyrroles with Malononitrile.Molecules (Basel, Switzerland) · 2022Article
- Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug-A Review.Molecules (Basel, Switzerland) · 2022Review
- Antitumor Properties of Epitope-Specific Engineered Vaccine in Murine Model of Melanoma.Marine drugs · 2022Article
- Largazole Inhibits Ocular Angiogenesis by Modulating the Expression of VEGFR2 and p21.Marine drugs · 2021Article
- Chondroprotective Effects of a Histone Deacetylase Inhibitor, Panobinostat, on Pain Behavior and Cartilage Degradation in Anterior Cruciate Ligament Transection-Induced Experimental Osteoarthritic Rats.International journal of molecular sciences · 2021Article
- Evaluation of Dimer of Epicatechin from an Endophytic FungusMolecules (Basel, Switzerland) · 2021Article
- Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges.Frontiers in cell and developmental biology · 2021Review
- Antiangiogenic molecules from marine actinomycetes and the importance of using zebrafish model in cancer research.Heliyon · 2020Review
- Marine Natural Products: A Source of Novel Anticancer Drugs.Marine drugs · 2019Review
- A marine sponge associated fungal metabolite monacolin X suppresses angiogenesis by down regulating VEGFR2 signaling.RSC advances · 2019Article
- Marine sponges of the genusActa pharmaceutica Sinica. B · 2019Review
- Article
- Angiosuppressive properties of marine-derived compounds-a mini review.Environmental science and pollution research international · 2017Review
- Ginseng Metabolites on Cancer Chemoprevention: An Angiogenesis Link?Diseases (Basel, Switzerland) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities. Compared with the drugs in the clinic, these agents display interesting characteristics, including diverse sources, unique chemical structures, special modes of action, and distinct activity and toxicity profiles. This review will first provide an overview of the current marine-derived angiogenesis inhibitors based on their primary targets and/or mechanisms of action. Then, the marine-derived antiangiogenic protein kinase inhibitors will be focused on. And finally, the clinical trials of the marine-derived antiangiogenic agents will be discussed, with special emphasis on their application potentials, problems and possible coping strategies in their future development as anticancer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.